We love to hear from our listeners. Send us a message.

As biotech capital markets continue to restrict access to funding for emerging biopharmas, you might be surprised by how many federal dollars get left on the negotiating table.  To that end, James Thomas Coates, Ph.D. and his team at Decisive Point have carved out a niche in the venture capital space. The firm specializes in helping biotech startups realize direct routes to millions of dollars in federal funding from a host of not-so-intuitive federal institutions—NASA, and the US Navy, Air Force, and Army, for instance—and helping them optimize funding from more obvious federal agencies such as DARPA and the NIH. On this episode of the Business of Biotech, Dr. Coates shares strategies and resources for tapping into biopharma capital that's ripe for the taking.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: [email protected]

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/